Latest news
EXEL: Q2 2026 revenues rose 10% year-over-year, with Zanza's CRC NDA under review and guidance trimmed - tradingview.comtradingview.com · Wed, 05 Aug 2026 23:25:49 GMTEXEL: Q2 2026 revenues rose 10% year-over-year, with pivotal trials advancing for future growth - tradingview.comtradingview.com · Wed, 05 Aug 2026 22:48:17 GMTEXEL: Q2 2026 revenues grew 11% YoY, with strong CABOMETYX sales and advancing zanzalintinib pipeline - tradingview.comtradingview.com · Wed, 05 Aug 2026 22:47:21 GMTEXEL: Q2 2026 saw revenue and net income growth, robust cabozantinib sales, and expanded R&D pipeline - tradingview.comtradingview.com · Wed, 05 Aug 2026 20:21:16 GMTPrice to book forward of EXEL Industries SA – FWB:8YK - tradingview.comtradingview.com · Sat, 01 Aug 2026 04:01:27 GMT